Functionally, in patient-derived and murine HCC models, TREM2 loss restored CD8+ T-cell infiltration and potentiated anti-PD-L1 efficacy, nominating TREM2+ TAMs as actionable suppressors (with particular enrichment after TACE) [36]. The gene discussed is TREM2; the disease is hepatocellular carcinoma.